Genenta Science S.p.A. Annual Report - How They Did This Year

I’m putting together a plain-English guide to help you understand Genenta Science’s performance this year. My goal is to break down complex filing information into simple terms so you can decide if this company fits your investment strategy.

1. What does this company do and how did they perform?

Genenta Science is a biotech company in the testing phase. They develop gene therapies using stem cells to treat solid tumors. Their platform, Temferon™, uses modified cells to deliver medicine directly to a tumor. As of December 31, 2025, they had 23.4 million shares outstanding. This year, they focused on advancing Temferon through early-stage clinical trials for brain cancer and other solid tumors. They also maintained partnerships with institutions like the Ospedale San Raffaele in Milan to help produce their treatments and run trials.

2. Financial performance

Genenta is not yet selling products, so they reported zero revenue. They had an operating loss of about €11.2 million, driven by €7.5 million in research and development and €3.7 million in general business costs. To fund these operations, the company relies on selling shares. In early 2026, they raised approximately $5 million through a stock offering to extend their operational runway.

3. Major wins and challenges

The company successfully managed its cash flow to maintain operations through the second half of 2026 while keeping clinical trials on track. The primary challenge remains the high cost of manufacturing treatments and monitoring patients. Because research costs represent the bulk of their budget, the company faces ongoing pressure to demonstrate positive clinical results to justify future fundraising efforts.

4. Financial health

Genenta ended the year with approximately €8.4 million in cash. With a monthly burn rate of €0.8 million to €1.0 million, their financial stability is tied to their ability to secure additional capital. They maintain a lean team and leverage academic partnerships to minimize overhead and preserve cash for critical clinical milestones.

5. Key risks

The company’s success is tied to the outcome of their clinical trials; if Temferon fails to outperform current treatments, the company’s primary asset loses its value, which could lead to a significant decline in share price. Furthermore, the company’s frequent issuance of new shares to raise capital dilutes existing ownership. Because they rely heavily on external funding, they are also highly sensitive to broader market volatility, which can make raising necessary capital more difficult or expensive.

6. Future outlook

The company’s future depends on proving the efficacy of their treatment. Management is focused on releasing updated safety and effectiveness data from current trials while simultaneously seeking partnerships with larger pharmaceutical companies. These potential collaborations are intended to provide additional funding or development support, with the long-term goal of a licensing deal or acquisition.

Investor Takeaway: Genenta is a high-risk, high-reward biotech play. Because they have no revenue and rely on share sales to fund research, your investment is essentially a bet on the success of their clinical trials. If you are considering an investment, look closely at their upcoming clinical data releases, as these will likely be the primary drivers of the stock's performance in the near term.